VentureBeat

TODAY’S HEADLINES:

• Stent maker IDev Tech raises $25M (VentureWire)
• Xytis gets $15M for brain-injury drugs (VentureWire)
• Diagnostic maker Iris Biotech plans to go public, launch breast-cancer test (Edgar)
• RiverVest Venture Partners raises $75M life-science fund (release)
• Concentric Medical names Maria Sainz CEO (release)

[Note: I'm a little sad to announce that this will be my last life-science briefing at VentureBeat, although with luck, it won't be the end of my time here. Starting Monday, I'll be blogging regularly on the drug industry and healthcare over at BNET Industries, a new CNET venture, so drop by if you can. (Preparing for that move is the main reason non-briefing posts have been scarce recently.) I still hope to post here occasionally as well, since covering below-the-radar startups has been a blast, and I'm not ready to give it up quite yet.

It's been a great year -- my first VentureBeat post was on April 3, 2007 -- and I want to thank Matt for the opportunity to join you here, and all our regular readers and commenters for your time and your insights. As journalists, we're only as good as our sources and readers, and you guys have helped in countless ways to make me look much smarter than I really am. --D.P.H.]

Stent maker IDev Tech raises $25M – IDev Technologies, a Houston medical-device startup, raised $25 million in a third funding round, VentureWire reports. The company is developing a new type of stent for use in propping open the liver’s bile ducts .

The company’s existing investors, a group that includes Bay City Capital, Heron Capital, PTB Sciences and RiverVest Venture Partners, provided the funding. IDev had previously raised $24 million, according to VW.

Xytis gets $15M for brain-injury drugs – Irvine, Calif.-based Xytis, a biotech focused on disorders of the central nervous system, raised $15 million in an extension of its second funding round, VentureWire reports. Its backers included Atlas Venture, CDC Innovation, Sanderling Ventures and Ventech.

The company says it was founded in 2005 from the merger of Xytis Pharmaceuticals and Remergent. (Sounds more to me like Xytis swallowed Remergent, but they’re free to describe it however they’d like.) Its lead drug candidate, XY2405, blocks a cellular protein called the Bradykinin B2 receptor, a signaling molecule thought to promote inflammation.

Xytis is testing the drug as a potential treatment for traumatic brain injury; the molecule is currently in mid-stage, phase II trials. The company is also testing an antidepressant in early-stage trials.

Xytis raised half the money last August, then received the second $7.5 million in April, the company told VentureWire. It has previously raised $24.5 million in its current incarnation, and its “predecessor companies” pulled in $6.5 million.

Diagnostic maker Iris Biotech plans to go public, launch breast-cancer test – Santa Clara, Calif.-based Iris Biotechnologies, a developer of molecular diagnostic tests, is preparing to go public, VentureWire reports. The company plans a small offering on the OTC Bulletin Board — if I’m reading its latest SEC filing correctly, its existing shareholders will raise about $1.1 million, with no proceeds headed to the company  — and hopes to launch a breast-cancer test later this year.

Iris plans to use chips to measure gene activity in breast cancer, with the hope of predicting the odds that a surgically removed tumor will recur and, eventually, helping patients and doctors customize cancer treatment from an early stage. The company claims that it will be competitive with Genomic Health and Agendia, two companies with similar tests for predicting breast-cancer recurrence.

There’s something a little odd about Iris’ disclosures in the SEC forms, though. Iris doesn’t describe its technology, the genes it will test or how it settled on them in any detail, and spends almost as much time talking about its database of patient information and related computer technology as it does about its tests. While it may consider some or all of that information a trade secret — and disclosure requirements may well be looser for such a small offering — it’s still kind of unusual for a startup to ask outside investors to put up their money essentially on faith.

Here’s the latest action:

Rulings could make website owners more vulnerable to lawsuits — Decisions made by judges in two separate cases, against Friendfinder.com and Roommates.com, could expose websites to potentially harmful lawsuits, according to an article on CNET. Websites were previously immune to most lawsuits based on content added to their sites by others.

Video search firm Meevee wants to throw in the towel — “Combining with an established player will maximize the potential for the community, technology and content relationships the company has built,” in-video search company Meevee said in a press release yesterday. Translation: Despite some growth, 1.1 million unique users per month just isn’t cutting it for a company that took $27 million in funding. Investors included Bay Area Equity Fund, Defta Partners, FCPR Israel Discovery Fund, Labrador Ventures, Rothschild Ventures and WaldenVC, according to peHUB. We wrote more about the company’s business model here.

Scientists learn to map CO2 emissions — Researchers have found a way to do daily tracking of carbon dioxide emissions based on locality. Preliminary results show the Southeast is an even heavier emitter than previously realized (but California produces a lot, too). It seems likely that such maps could someday be used to help address problem areas, when attempting to scale back emissions.

EMC lays down $213M for storage firm Iomega — Iomega, the maker of the popular branded storage drives Zip and Rev, sold itself to information infrastructure company EMC for $213 million. EMC has three main divisions, in content management, information security and storage; the acquisition should help it expand further into the consumer market.

Nimsoft acquires Indicative Software — Nimsoft works in the information technology management field, competing with the “Big Four” made up of Hewlett-Packard, CA, IBM and BMC, while Indicative Software makes domain monitoring and end-user experience testing tools for IT departments. The acquisition price was not disclosed. Indicative had taken $19 million from Sequel Venture Partners, Sutter Hill Ventures and Vista Ventures. [Red Herring]

Search engines pressured to delete user info more quickly in Europe – Google and other search engines should delete info showing what users searched for within six months, says the European Commission, which is considering making the suggestion a commandment. Google global privacy counsel Peter Fleischer claims the data should be kept for up to 18 months in order to help protect user’s identities, but the argument may not sway the EU. Thanks to the global nature of the internet, any decision made overseas may well be reflected at home.

Mytopia raises part of first round for cross-platform gaming — We recently wrote about Mytopia, which is working on connecting games across platforms like Facebook and MySpace. It’s raised about half of a sub-$5 million first round of funding, according to VentureWire. Update: According to Mytopia itself, they’re simply “in the midst” of raising a first round, and have not disclosed the total amount they’re aiming for.

Floating solar balloons proposed to power remote regions — Israel’s Technion Institute of Technology has created a design for floating, thin-film solar cell-coated balloons capable of generating about a kilowatt of power each, aimed at powering remote regions. It plans to start selling them in spring 2009. One question: Don’t remote regions, almost by definition, have plenty of free space on the ground? [Reuters via Ecogeek]